Effects of Dapagliflozin and Dapagliflozin-Saxagliptin on Erythropoiesis, Iron and Inflammation Markers in Patients with Type 2 Diabetes and Chronic Kidney Disease: Data from the DELIGHT Trial

By
Laurisa Dohm
-
0
50
Researchers measured hemoglobin, iron markers, plasma erythropoietin, and inflammatory markers at baseline and week 24.
[Cardiovascular Diabetology]
Full Article